NCT00603915View on ClinicalTrials.gov

A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

April 30, 2011

Conditions
Nasopharyngeal Cancer
Interventions
DRUG

Gemcitabine

1000mg/m\^2 intravenous (IV) day 1 and day 8

DRUG

Carboplatin/Cisplatin

Area under curve (AUC)=5 (Carboplatin) or 70mg/m\^2 (Cisplatin) intravenous (IV) day 1

DRUG

erlotinib

150mg daily (post GC therapy)

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT00603915 - A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer | Biotech Hunter | Biotech Hunter